The CHOLEGAS study: multicentric randomized, blinded, controlled trial of gastrectomy plus prophylactic cholecystectomy versus gastrectomy only, in adults submitted to Gastric cancer surgery with curative intent by Farsi, Marco et al.
BioMed  Central
Page 1 of 5
(page number not for citation purposes)
Trials
Open Access Study protocol
The CHOLEGAS study: multicentric randomized, blinded, 
controlled trial of gastrectomy plus prophylactic cholecystectomy 
versus gastrectomy only, in adults submitted to Gastric cancer 
surgery with curative intent
Marco Farsi1, Marco Bernini1, Lapo Bencini*1, Egidio Miranda1, 
Roberto Manetti1, Giovanni de Manzoni2, Giuseppe Verlato3, 
Daniele Marrelli4, Corrado Pedrazzani4, Francesco Roviello4, 
Alberto Marchet5, Luigi Cristadoro6, Leonardo Gerard7, Renato Moretti1 for 
GIRCG (Gruppo Italiano di Ricerca sul Cancro Gastrico)
Address: 1General and Oncologic Surgery, Careggi Hospital, Florence, Italy, 2First Department of General Surgery, University of Verona, Italy, 3Unit 
of Epidemiology and Medical Statistics, University of Verona, Italy, 4Department of Surgery, University of Siena, Italy, 5Department of Surgery, 
University of Padova, Italy, 6General Surgery, Pieve di Coriano Hospital, Mantova, Italy and 7General Surgery, Ospedale Carlo Poma, Mantova, 
Italy
Email: Marco Farsi - marco.farsi@tin.it; Marco Bernini - marco.bern@tin.it; Lapo Bencini* - lapbenc@tin.it; Egidio Miranda - egmir@tin.it; 
Roberto Manetti - lapbenc@tin.it; Giovanni de Manzoni - giovanni.demanzoni@univr.it; Giuseppe Verlato - giuseppe.verlato@univr.it; 
Daniele Marrelli - marrelli@unisi.it; Corrado Pedrazzani - pedrazzani@unisi.it; Francesco Roviello - roviello@unisi.it; 
Alberto Marchet - marchet@unipd.it; Luigi Cristadoro - luigi.cristadoro@tin.it; Leonardo Gerard - leon.gerard@tiscali.it; 
Renato Moretti - morettir@aou-careggi.toscana.it; GIRCG (Gruppo Italiano di Ricerca sul Cancro Gastrico) - lapbenc@tin.it
* Corresponding author    
Abstract
Background: The incidence of gallstones and gallbladder sludge is known to be higher in patients after gastrectomy than
in general population. This higher incidence is probably related to surgical dissection of the vagus nerve branches and the
anatomical gastrointestinal reconstruction. Therefore, some surgeons perform routine concomitant cholecystectomy
during standard surgery for gastric malignancies. However, not all the patients who are diagnosed to have cholelithiasis
after gastric cancer surgery will develop symptoms or require additional surgical treatments and a standard laparoscopic
cholecystectomy is feasible even in those patients who underwent previous gastric surgery. At the present, no
randomized study has been published and the decision of gallbladder management is left to each surgeon preference.
Design: The study is a randomized controlled investigation. The study will be performed in the General and Oncologic
Surgery, Department of Oncology – Azienda Ospedaliero-Universitaria Careggi – Florence – Italy, a large teaching
institution, with the participation of all surgeons who accept to be involved in, together with other Italian Surgical
Centers, on behalf of the GIRCG (Italian Research Group for Gastric Cancer).
The patients will be randomized into two groups: in the first group the patient will be submitted to prophylactic
cholecystectomy during standard surgery for curable gastric cancer (subtotal or total gastrectomy), while in the second
group he/she will be submitted to standard gastric surgery only.
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Introduction
The incidence of gallstones and gallbladder sludge is
known to be higher in patients after gastrectomy than in
general population (15–25% versus 5%, 5 years after gas-
tric surgery) [1-4]. This higher incidence is probably
related to surgical dissection of the vagus nerve branches
and the anatomical gastrointestinal reconstruction [5-7].
Moreover, the risk of developing gallstones may depend
on the extent of gastrectomy (subtotal or total) and lym-
phadenectomy (D1 or D2) [4,8-10]. Concomitant chole-
cystectomy is not time consuming and substantially
without additional risks for the patients, because compli-
cations during another abdominal procedure are known
to be minimal [11-13]. In addition theoretic advantages
will be represented by the avoidance of reintervention for
cholelithiasis only.
However, not all the patients who are diagnosed to have
cholelithiasis after gastric cancer surgery will develop
symptoms or require additional surgical treatments [2-4]
and a standard laparoscopic cholecystectomy is feasible
even in those patients who underwent previous gastric
surgery[14].
Due to the lack of specific data and to presence of con-
trasting studies, some Authors[4,8] recommend to per-
form a prophylactic cholecystectomy at the time of gastric
surgery to avoid complications and impairment of quality
of life in surviving patients, while others do not[1]. At the
present, no randomized study has been published and the
decision of gallbladder management is left to each sur-
geon preference.
Methods
Ethical Approval
The Cholegas Study was approved by the ethical Commit-
tee of the Careggi Hospital, Florence, Italy (and from all
the local Committes of the participating centers).
Design
The study is a controlled randomized trial. The study will
be performed in the General and Oncologic Surgery,
Department of Oncology – Azienda Ospedaliero-Univer-
sitaria Careggi – Florence – Italy, a large teaching institu-
tion, with the participation of all surgeons who accept to
be involved in, together with other Italian Surgical Cent-
ers, on behalf of the GIRCG (Italian Research Group for
Gastric Cancer).
The patients will be randomized into two groups: in the
first group the patient will be submitted to prophylactic
cholecystectomy during standard surgery for curable gas-
tric cancer (subtotal or total gastrectomy), while in the
second group he/she will be submitted to standard gastric
surgery only.
Randomization
The randomization will be obtained through a computer-
generated program (GraphPad Software, Inc, La Jolla, Cal-
ifornia, USA). The randomization, will be done before the
beginning of the study and it will consist with an ordered
series of numbers with a corresponding letter: A for pro-
phylactic cholecystectomy and B for gastrectomy only.
This series of numbers will be kept in the Department of
General and Oncologic Surgery in Florence and after gas-
tric cancer diagnosis if the patient fulfills the inclusion cri-
teria, either from Florence or from any other Center
throughout Italy, and signs the consent a number, pro-
gressive as in order of inclusion, will be assigned to him
or her. The letter corresponding to the number, and hence
the type of procedure to perform, will be notify to the
operating surgeon, who will proceed accordingly.
Statistics
Power Calculations
To compute sample size, the proportion of patients free
from cholelithiasis was assumed to be 100% 5 years after
gastrectomy plus prophylactic cholecystectomy. It is
known from the current literature that the cumulative
incidence of cholelitiasis 5 years after gastrectomy is
around 15–25% while in the general population 5 years
cumulative incidence is around 5% [1-4]. The 5-yr cumu-
lative incidence of cholelithiasis after cholecystectomy is
known to be null. Hence we assumed a 5 years cumulative
incidence of 20% in patients undergoing gastrectomy
alone and of 0% in patients undergoing gastrectomy +
cholecystectomy.
Gastrectomy with concomitant cholecystectomy was
assumed to increase cholelithiasis-free survival from 80%
to 100%. Assuming a constant accrual rate and an accrual
time of 2 years, a minimum follow-up period of 3 years,
an overall survival probability of 50% at 5 years, 122
patients (61 in the control group and 61 in the cholecys-
tectomy group) are necessary to ensure an 80% power
with an alpha of 5%, when using a two-sided log-rank
test.
Assuming a 50% drop-out rate during a 3 years follow-up
allows to account for both cancer mortality and follow-up
loss. These assumptions were based on the fact that com-
peting events (deaths) will be substantial while patients
lost from follow-up will be few. In a GIRCG series of 1032
patients undergoing gastrectomy plus lymphadenectomy
3 years disease-related survival was 59% (95% CI 41–
60%), while no patient was lost to follow-up in the first 3
years after gastrectomy[15]. Therefore, to be conservative,
we assumed a 50% loss during a follow-up period of threeTrials 2009, 10:32 http://www.trialsjournal.com/content/10/1/32
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years, to account for both cancer mortality and loss to fol-
low-up.
The statistical power sample calculation was carried out
using PASS 2005 (Power Analysis and Sample Size, within
the statistical package "NCSS 2004 and PASS 2005")[16]
(see additional file 1).
Tests
To evaluate significance of differences between the two
groups, chi-squared and Fisher's exact test will be used as
appropriated for categorical variables, and the non-para-
metric Mann-Whitney U-test for continuous variables. To
evaluate differences in the incidence of cholelithiasis,
Kaplan-Meier survival curves will be computed consider-
ing as endpoint the onset of cholelithiasis itself. Survival
curves will be compared by log-rank test and multivaria-
ble analysis will be accomplished by the Cox regression
model. Significance level will be set at 5%. The statistical
analysis will be carried out using the Statistical Package for
the Social Sciences (SPSS version 13; SPSS Inc. Chicago,
Illinois, USA).
Inclusion and exclusion criteria
Inclusion criteria
￿ Patients suitable for curative surgery ≤ 80 years old
￿ Histhopatological confirmed gastric cancer (adeno-
carcinoma)
￿ Informed consent
Exclusion criteria
￿ Informed consent refusal
￿ Previous cholecystectomy
￿ Demonstrated cholelithiasis or biliary sludge
￿ Metastatic disease
￿ Metabolic diseases that may favour gallstones forma-
tion (hemolytic anemia, genetic hypercholestero-
lemia)
Intervention
Preoperative data collection will include patient demo-
graphics and comorbidities (genitourinary, cardiac, pul-
monary, gastrointestinal, renal, or rheumatologic).
The standard surgery for gastric cancer includes both total
and subtotal gastrectomy with lymphadenectomy (D1,
D2, D3), either laparoscopic or laparotomic. All types of
reconstructions are allowed, including either mechanic or
hand-sewn anastomosis. The standard open or laparo-
scopic cholecystectomy includes Calot's dissection with
the cystic duct and artery ligated prior removal. The fun-
dus-first technique is also allowed. Drainage tubes are left
on routine basis, and withdrawn according to surgeon's
preference.
Data Collection
Patients' data files are generated containing demographic
data and preoperative, operative, and postoperative infor-
mation.
Pre-operative notes concern the history of gastric symp-
toms, the presence of associated diseases (cardiac, hyper-
tension, diabetes, malignancy), duration of complaints
(as an indication for the onset of the disease), and labora-
tory results of WBC count, serum bilirubin, gamma GT,
and alkaline phosphatase. Ultrasound preoperative exclu-
sion of gallbladder diseases is mandatory.
Operative data of concern are confirmation of a normal
gallbladder, type of gastrectomy (subtotal or total), extent
of lymphadenectomy (D1, D2 and 12th node station, D3)
and reconstruction. Postoperative notes of interest
include the use of Total Parenteral Nutrition (TPN) or
Enteral Nutrition (EN), complications, and length of hos-
pital stay. Laboratory tests of WBC count, serum bilirubin,
gamma GT, and alkaline phosphatase are also collected in
postoperative days 3rd and 7th.
Complications are classified as surgical infections (wound
infection, subphrenic or subhepatic abscesses); noninfec-
tious surgical problems (e.g. anastomotic leakage, bile
duct injury, hemorrhage); remote infections (urinary or
respiratory); and miscellaneous problems (e.g. pulmo-
nary complications, deep venous thrombosis, cardiac
complications, etc). The collected information are entered
into a database as either continuous or categorical varia-
bles for statistical analysis.
A second surgeon (different from the one who participat-
ing in the intervention), aware of the operative findings
but not the management of the gallbladder, will then
assume the care of the patient. Postoperative care and
ability to be discharged from the hospital will be deter-
mined by the second surgical team. This second surgical
team will be blinded to the treatment of the gallbladder.
The primary operative team will be in every moment
available for emergent consultation.
Patient discharge will be based on good medical practice
criteria: 1) apyrexia 2) absence of diseases requiring hos-
pitalisation 3) light meals tolerance 4) return of bowel
function 5) patient's compliance. A routine ultrasonogra-Trials 2009, 10:32 http://www.trialsjournal.com/content/10/1/32
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phy of hepathobiliary region will be scheduled after 4 and
every 6 months for the first two years and yearly for the
rest of the follow-up (at least 5 years) to assess possible
cholelithiasis development. Routine blood check with
specific hepatic tests will be collected with the same sched-
ule. Routine oncologic follow-up in an outpatient setting
are also added according to current protocols.
Informed consent
In the informed consent patients will receive all the infor-
mation about the study protocol, the confidential nature
of personal data and will fill up a questionnaire before
signing or refuse.
There will be not inconveniences caused to the patients.
No incentives are planned for the patients regarding the
operation or the follow-up. All the medical information
obtained from the patients will be kept confidential
among the research scientists conducting the study.
The patients will be free to withdraw from the study when-
ever they want without any obligation. The stopping rules
will be applied also in case of newly discovered statisti-
cally significant advantages or disadvantages in one
group.
Finishing and reporting dates
The study will take approximately 1 – 3 years for the inclu-
sion period. According to the number of gastrectomies
managed monthly in all Centers, the duration of the
inclusion period can be approximately 2 years to reach the
number of about 122 enrolled patients.
An interim report is planned at the end of any completed
follow-up period.
Primary aims of the study
The aim of the study is to compare the results of gastrec-
tomy plus prophylactic cholecystectomy versus gastrec-
tomy only in patients undergoing gastric cancer surgery
with a curative intent, in terms of morbidity, mortality,
operation time, hospital stay, postoperative pain, return
to normal activity, quality of life, and development of bil-
iary symptoms after 5 years from surgery.
The primary aims of our study will be:
A) To evaluate whether patients who had not a pro-
phylactic cholecystectomy and developed cholelithia-
sis will eventually suffer from symptoms related to
their gallstones and will need another surgical inter-
vention 5 years after gastrectomy
B) To evaluate the incidence of cholelithiasis in
patients who have undegone gastric surgery
C) To evaluate whether prophylactic cholecystectomy
increases complications rate, operative time and post-
operative stay.
The onset of any other complications will be recorded
intraoperatively, postoperatively, at discharge, 4-months
after surgery. Subsequently, visits will be scheduled every
6-months in first two years after surgery, and yearly there-
after till completion of the 5-year follow-up.
Conclusion
Gallbladder disease is common after gastrectomy for can-
cer. Any improvement in this field will benefit many
patients improving their quality of life and reducing mor-
bidity, mortality, and hospital stay. Complications from
cholecystectomy during another abdominal procedure are
known to be minimal. The treatment group is not
expected to experience dangerous complication because
concomitant cholecystectomy is a very simple procedure.
On the other hand, theoretic advantages will be repre-
sented by the avoidance of reintervention for cholelithia-
sis only.
All our patients will be informed about the study and an
informed consent will be obtained. According to the best
of our knowledge, there will not be any additional incon-
veniences caused to the patients. All the medical informa-
tion obtained from the patients will be kept confidential
among the research scientists conducting the study. The
patients will be free to withdraw from the study, whenever
they want without any obligation.
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